3 results
Primary:• To compare the overall survival (OS) of patients in the rigosertib group vs the Physician*s Choice group, in all patients and in a subgroup of patients with IPSS-R very high riskSecondary efficacy• To compare rigosertib to Physician*s…
Main objective:Dose Escalation Part:• To assess the safety and tolerability of DF1001, and to determine the Maximum Tolerated Dose (MTD) of DF1001 in patients with Advanced (unresectable, recurrent, or metastatic) solid tumors for whom no effective…
PRIMARY QUESTIONDuring the sentinel node procedure in breast cancer patients, does a 3D SPECT/CT protocol not lead to a longer operation time to remove axillary sentinel nodes, compared to the 2D standard protocol?• H0: OK-time(SPECT/CT) - OK-time(…